Abstract:Microtubule associated protein tau (tau) deposition is associated with a spectrum of neurodegenerative diseases collectively termed tauopathies. We have previously shown that amyotrophic lateral sclerosis (ALS) with cognitive impairment (ALSci) is associated with tau phosphorylation at Thr175 and that this leads to activation of GSK3β which then induces phosphorylation at tau Thr231. This latter step leads to dissociation of tau from microtubules and pathological tau fibril formation. To determine the extent to which this pathway is unique to ALS, we have investigated the expression of pThr175 tau and pThr231 tau across a range of frontotemporal degenerations. Representative sections from the superior frontal cortex, anterior cingulate cortex (ACC), amygdala, hippocampal formation, basal ganglia, and substantia nigra were selected from neuropathologically confirmed cases of Alzheimer’s disease (AD; n = 3), vascular dementia (n = 2), frontotemporal lobar degeneration (FTLD; n = 4), ALS (n = 5), ALSci (n = 6), Parkinson’s disease (PD; n = 5), corticobasal degeneration (CBD; n = 2), diffuse Lewy body dementia (DLBD; n = 2), mixed DLBD (n = 3), multisystem atrophy (MSA; n = 6) and Pick’s disease (n = 1) and three neuropathologically-normal control groups aged 50–60 (n = 6), 60–70 (n = 6) and 70–80 (n = 8). Sections were examined using a panel of phospho-tau antibodies (pSer208,210, pThr217, pThr175, pThr231, pSer202 and T22 (oligomeric tau)). Across diseases, phospho-tau load was most prominent in layers II/III of the entorhinal cortex, amygdala and hippocampus. This is in contrast to the preferential deposition of phospho-tau in the ACC and frontal cortex in ALSci. Controls showed pThr175 tau expression only in the 7th decade of life and only in the presence of tau pathology and tau oligomers. With the exception of DLBD, we observed pThr175 co-localizing with pThr231 in the same cell populations as T22 positivity. This suggests that this pathway may be a common mechanism of toxicity across the tauopathies.

Tubular aggregates in paralysis periodica paramyotonica with T704M mutation of SCN4A.

The autosomal dominant inheritance tubular aggregate myopathy with SCN4A gene mutation

N1366S Mutation of Human Skeletal Muscle Sodium Channel Causes Paramyotonia Congenita

Study on Aggregate Formation Mechanism of HSPB8 Gene Mutation Resulting in CMT2L

Dysfunction of microtubule-associated proteins of MAP2/tau family in Prion disease.

A Familial Late-Onset Hereditary Ataxia Mimicking Pontocerebellar Hypoplasia Caused by A Novel Tsen54 Mutation

Dysfunction of Microtubule-Associated Proteins of MAP2/tau Family in Prion Disease

Clinical Phenotypes and Pathological Features in Myopathies with Tubular Aggregates

Genetic defects are common in myopathies with tubular aggregates

Intronic Pentanucleotide TTTCA Repeat Insertion in the SAMD12 Gene Causes Familial Cortical Myoclonic Tremor with Epilepsy Type 1

Clinical, Myopathological Features and Sodium Channel Α-Subunit Encoding Gene Mutation Analysis in 17 Patients with Skeletal Muscle Sodium Channelopathies

Clinical Comparison and Functional Study of the L703P: a Recurrent Mutation in Human SCN4A That Causes Sodium Channel Myotonia.

The R900S Mutation in CACNA1S Associated with Hypokalemic Periodic Paralysis

Clinical Features of Myopathy with Tubular Aggregates:6 Cases

Novel TUBA4A variant causes congenital myopathy with focal myofibrillar disorganisation

Normokalemic and Hypokalemic Periodic Paralysis Coexist in a Family with a Novel R1129Q Mutation in the SCN4A Gene

Tuberous sclerosis complex is associated with a novel human tauopathy

TAU FILAMENTS WITH THE CHRONIC TRAUMATIC ENCEPHALOPATHY FOLD IN A CASE OF VACUOLAR TAUOPATHY WITH MUTATION D395G

Threonine175, a novel pathological phosphorylation site on tau protein linked to multiple tauopathies

Myofibrillar Myopathy with Cytoplasmatic.spheroid Bodies: a Report of a Chinese Family

Novel mutations in Chinese Han patients with tuberous sclerosis complex: Case series and review of the published work.